Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian’s Biotron Focuses On Developing Drug For Spreading Dengue

This article was originally published in PharmAsia News

Executive Summary

Australian biotech Biotron and two universities are focusing on a drug to treat the dengue fever plaguing parts of the country. No drug or vaccine is available today to treat the disease and patients have to rely instead on treatments for the symptoms. The researchers are attempting to develop a drug that slows growth or at least inhibits the infection of the virus by binding with the proteins responsible. One of the scientists said the dengue virus is able to suppress some of the human's antiviral proteins, making it effective as a disease. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel